Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Receivables: 2019-2024

Historic Receivables for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $56.4 million.

  • Pharming Group N.V's Receivables fell 9.53% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.8 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $56.4 million for FY2024, which is 16.80% up from last year.
  • Per Pharming Group N.V's latest filing, its Receivables stood at $56.4 million for FY2024, which was up 16.80% from $48.3 million recorded in FY2023.
  • Over the past 5 years, Pharming Group N.V's Receivables peaked at $56.4 million during FY2024, and registered a low of $28.7 million during FY2022.
  • In the last 3 years, Pharming Group N.V's Receivables had a median value of $48.3 million in 2023 and averaged $44.5 million.
  • Its Receivables has fluctuated over the past 5 years, first fell by 15.34% in 2021, then surged by 68.09% in 2023.
  • Yearly analysis of 5 years shows Pharming Group N.V's Receivables stood at $38.2 million in 2020, then fell by 15.34% to $32.3 million in 2021, then dropped by 11.16% to $28.7 million in 2022, then surged by 68.09% to $48.3 million in 2023, then rose by 16.80% to $56.4 million in 2024.